“Evaluation of Risk Markers Fluctuation During an Initial Therapy with Rosiglitazon in Patients Suffering from Metabolic Syndrome” (2009) Biomolecules and Biomedicine, 9(4), pp. 320–328. doi:10.17305/bjbms.2009.2788.